End-stage renal disease Urological and Genital Diseases
Conditions
Interventions
A simple randomization method was used to select participants from the eligible candidates. Group allocation, determined by the dialyzer type, was also assigned through randomization based on each pat
Sponsors
Nipro (Japan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Being on renal replacement therapy with hemodialysis for at least 3 months prior to inclusion
Exclusion criteria
Exclusion criteria: 1. Patients with treatment regimens of fewer than three sessions per week 2. Minors 3. Patients hospitalized or deceased during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pre- and post-dialysis levels of creatinine (mg/dL), urea (mg/dL), phosphorus (mg/dL), parathyroid hormone (PTH, pg/mL), and albumin (g/dL) measured using blood sample analysis at the laboratory of Torrecárdenas University Hospital in blood samples collected during the second weekly session of each patient | — |
Secondary
| Measure | Time frame |
|---|---|
| Pre- and post-dialysis levels of beta-2 microglobulin (mg/L), myoglobin (ng/mL), C-reactive protein (CRP, mg/L), procalcitonin (ng/mL), and interleukin-6 (IL-6, pg/mL) measured using blood sample analysis at the laboratory of Torrecárdenas University Hospital in blood samples collected during the second weekly session of each patient | — |
Countries
Spain
Contacts
Public ContactJavier Ramírez Santos
Outcome results
None listed